Occurrence of Pustular Psoriasis after Treatment of Crohn Disease with Infliximab

M.D., M.P.H. Crystal Y. Pourciau; Shwayder, Tor

doi:10.1111/j.1525-1470.2010.01267.x

Cited by 28 publications

(42 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of 37 cases of IBD in children, anti‐TNF‐α‐related psoriatic eruptions were mostly reported in patients with CD with no personal or family history of psoriasis receiving infliximab therapy and with the latency between initiation of anti‐TNF‐α therapy and onset of psoriatic lesions ranging from 0.5 to 41 months, which is consistent with the IBD adult literature .…”

Section: New‐onset or Worsening Of Psoriatic Lesions During Anti‐tumosupporting

confidence: 81%

Anti‐Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review

Romiti

Araujo

Steinwurz

et al. 2016

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

Section: New‐onset or Worsening Of Psoriatic Lesions During Anti‐tumosupporting

confidence: 81%

Anti‐Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review

Romiti

Araujo

Steinwurz

et al. 2016

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…However, these data must be cautiously interpreted because anti-TNF-α withdrawal can determine the aggravation of intestinal manifestations (3,8,17,31,38,40) . Based on the present review (1,-3, 5, 7-9, 11, 12, 15-18, 21-23, 25-31, 33-36, 38-44) , the IBD patients developing psoriasis during infliximab therapy must be treated by the conventional psoriasis approach (topical corticosteroids, phototherapy, vitamin-D analogs, methotrexate and/or cyclosporine) without the need to suspend infliximab.…”

Section: Discussionmentioning

confidence: 99%

The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?

Denadai¹,

Teixeira²,

Saad-Hossne³

2012

Arq. Gastroenterol.

View full text Add to dashboard Cite

CONTEXT: Several paradoxical cases of infliximab-induced or-exacerbated psoriatic lesions have been described in the recent years. There is disagreement regarding the need to discontinue infliximab in order to achieve the resolution of these adverse cutaneous reactions specifically in inflammatory bowel disease (IBD) patients. OBJECTIVE: To systematically review the literature to collect information on IBD patients that showed this adverse cutaneous reaction, focusing mainly on the therapeutic approach. METHODS: A systematic literature review was performed utilizing Medline, Embase, SciELO and Lilacs databases. Published studies were identified, reviewed and the data were extracted. RESULTS: Thirty-four studies (69 IBD patients) met inclusion criteria for review. There was inconsistency in reporting of some clinical and therapeutic aspects. Most patients included had Crohn's disease (89.86%), was female (47.83%), had an average age of 27.11 years, and no reported history of psoriasis (84.05%). The patients developed primarily plaque-type psoriasis (40.58%). There was complete remission of psoriatic lesions in 86.96% of IBD patients, existing differences in the therapeutic approaches; cessation of infliximab therapy led to resolution in 47.83% of cases and 43.48% of patients were able to continue infliximab therapy. CONCLUSION: As increasing numbers of IBD patients with psoriasis induced or exacerbated by infliximab, physicians should be aware of its clinical manifestations so that appropriate diagnosis and treatment are properly established. The decision whether to continue or discontinue infliximab should be individualized.

show abstract

“…Three additional case series and five case reports exist, including a recent series of 14 pediatric patients with IBD at one center who developed paradoxical psoriasis over a 13‐year period . These studies demonstrated an overall female predominance (except in one study of pediatric CD), low rates of personal/family histories of psoriasis, a preponderance for scalp involvement, and wide ranges of latency periods to psoriasis diagnosis following TNFi initiation …”

Section: Introductionmentioning

confidence: 99%

Tumor necrosis factor‐α inhibitor‐induced psoriasis in juvenile idiopathic arthritis patients

Groth

Pérez

Treat

et al. 2019

Pediatric Dermatology

View full text Add to dashboard Cite

Background/Objectives The development of psoriasis while on tumor necrosis factor inhibitors (TNFi) is a paradoxical effect of agents that treat psoriasis. There is a paucity of data available on this entity in juvenile idiopathic arthritis (JIA). Our objectives were to determine the prevalence of TNFi‐induced psoriasis in patients with JIA at two pediatric centers, and psoriasis response to therapeutic modifications. Methods We performed retrospective chart review on patients with JIA treated with TNFi (adalimumab, etanercept, infliximab) who developed psoriasis. TNFi‐induced psoriasis was defined as an incident diagnosis of psoriasis after starting a TNFi. Patients with personal histories of psoriasis prior to TNFi therapy were excluded. Following diagnosis, responses to medication changes were defined based on physician assessments. Results Nine of 166 (5.4%) patients on TNFi for JIA were diagnosed with TNFi‐induced psoriasis. All cases were female. One had a family history of psoriasis. The median age was 10 (range 2‐16) years. Five (55%) patients experienced scalp psoriasis, including four (44%) with alopecia. Two (22%) patients achieved significant improvement after switching to different classes of biologic agents, while three (33%) patients had significant improvement following discontinuation of biologic therapy. One of five patients who switched to a different TNFi had complete resolution, while four had worsening symptoms or partial improvement. Conclusions Our findings demonstrate the prevalence of TNFi‐induced psoriasis in JIA at two centers. Though larger studies are needed, our data suggest discontinuation of TNFi or biologic class switching should be considered as treatment strategies in select patients.

show abstract

Occurrence of Pustular Psoriasis after Treatment of Crohn Disease with Infliximab

Abstract: We report a case of pustular psoriasis induced by anti-TNF-α therapy in a 12-year-old boy with inflammatory bowel disease. This is a well-documented phenomenon but remains a clinical challenge, especially when presenting in the pediatric setting.

Cited by 28 publications

References 6 publications

Anti‐Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review

Anti‐Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review

The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?

Tumor necrosis factor‐α inhibitor‐induced psoriasis in juvenile idiopathic arthritis patients

Contact Info

Product

Resources

About